Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar
- 54 Downloads
Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.
KeywordsAdverse Drug Reactions Hamad Medical Corporation Medication safety Pharmacovigilance Qatar
Conflicts of interest
All the authors declare that they have no conflict of interest.
- 1.World Health Organization. Reporting and learning systems for medication errors: the role of pharmacovigilance centers. 2014. http://apps.who.int/medicinedocs/documents/s21625en/s21625en.pdf. Accessed 05 Feb 2018.
- 2.World Health Organization. International drug monitoring: the role of the hospital, report of a WHO meeting [held in Geneva from 18 to 23 November 1968]. 1969. http://apps.who.int/iris/bitstream/10665/40747/1/WHO_TRS_425.pdf. Accessed 05 Feb 2018.
- 11.Ministry of Development Planning and Statistics. Total population within the State of Qatar. 2017. http://www.mdps.gov.qa/portal/page/portal/gsdp_en/statistics_en/monthly_preliminary_figures_on_population_en. Accessed 10 Jan 2018.
- 12.Ministry of Public Health (MoPH) Qatar. Health objectives: ministry of public health. 2017. https://phs.moph.gov.qa/current-status/. Accessed 10 Jan 2018.
- 13.Ministry of Public Health, Qatar. Health services. 2018. https://www.moph.gov.qa/health-services/Pages/default.aspx. Accessed 22 Jan 2018.
- 14.National Health Strategy 2011–2016. Healthcare products regulation. General secretariat, supreme council of health. 2014. www.nhsq.info/strategy-goals-and./national-health/healthcare-products-regulation. Accessed 10 Jan 2018.
- 15.Joint Commission International (JCI). JCI-accredited organizations. 2017. https://www.jointcommissioninternational.org/about-jci/jci-accredited-organizations/?c=Qatar. Accessed 19 Dec 2017.
- 16.The Institute for Healthcare Improvement. Current collaborations in the region—Qatar-Hamad Medical Corporation. Institute for healthcare improvement. 2018. http://www.ihi.org/regions/MiddleEast/Pages/OurWork.aspx. Accessed 10 Jan 2018.
- 17.International Medication Safety Network (IMSN). Medication safety and quality center (MSQC): Qatar. 2018. https://www.intmedsafe.net/about/imsn-members/. Accessed 10 Jan 2018.
- 18.WHO Program for International Drug Monitoring. Associate members: Qatar. 2018. https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/. Accessed 10 Jan 2018.
- 20.ElKassem W, Al Hail M, Rouf A, Hamad A, Thomas B. An evaluation of knowledge, attitude and practice of pharmacists towards adverse drug reactions: a questionnaire based study at Hamad Medical Corporation, Qatar. 2017. https://www.eventscribe.com/2017/ASHPMeeting/ajaxcalls/PosterInfo.asp?efp=WUFORk1KUU8yMDk5&PosterID=117702&rnd=0.5433606. Accessed 10 Jan 2018.
- 23.Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A survey of knowledge, attitude and practice of nurses towards pharmacovigilance in Taleqani Hospital. Iran J Pharm Res (IJPR). 2010;9(2):199–206.Google Scholar